Stockscreener 앱 받기
1.434
3.18%
-0.036
전일 마감가:
$1.47
열려 있는:
$1.46
하루 거래량:
64,065
Relative Volume:
0.14
시가총액:
$77.14M
수익:
-
순이익/손실:
$-151.16M
주가수익비율:
-0.4828
EPS:
-2.97
순현금흐름:
$-130.08M
1주 성능:
-1.16%
1개월 성능:
+3.14%
6개월 성능:
+177.77%
1년 성능:
-1.84%
1일 변동 폭
$1.408
$1.50
1주일 범위
$1.408
$1.57
52주 변동 폭
$0.404
$2.27
AIx 온콜로지 Stock (ALXO) Company Profile
명칭
Alx Oncology Holdings Inc
전화
650-466-7125
주소
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
ALXO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.4228 | 79.70M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.49 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.26 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
842.80 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.79 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.79 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
AIx 온콜로지 Stock (ALXO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-06 | 개시 | UBS | Buy |
| 2021-02-10 | 개시 | H.C. Wainwright | Buy |
| 2020-08-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 개시 | Credit Suisse | Outperform |
| 2020-08-11 | 개시 | Jefferies | Buy |
| 2020-08-11 | 개시 | Piper Sandler | Overweight |
모두보기
AIx 온콜로지 주식(ALXO)의 최신 뉴스
Alx Oncology: A Study in Contrasting Market Sentiment - AD HOC NEWS
ALX Oncology (NASDAQ:ALXO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Alx Oncology rallies on strong phase 2 data for lymphoma therapy - MSN
Alx Oncology stock soars after impressive lymphoma treatment results By Investing.com - Investing.com UK
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ALX Oncology (Nasdaq:ALXO) Reports High Response Rates for Evorpacept Combo in Indolent B-cell NHL at ASH 2025 - Kalkine Media
ALXO: Promising Phase 2 Trial Results for Evorpacept in iNHL Tre - GuruFocus
Alx Oncology Holdings Inc. Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-Of-Care Treatment in Patients with Indolent B-Cell Non-Hodgkin Lymphoma, At Ashodgkinlymph - marketscreener.com
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - Sahm
ALX Oncology (NASDAQ:ALXO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
ALX Oncology (NASDAQ:ALXO) Stock Price Up 3.8%Here's Why - MarketBeat
Reviewing Harmony Biosciences (NASDAQ:HRMY) and ALX Oncology (NASDAQ:ALXO) - Defense World
Why ALX Oncology Holdings Inc. stock could benefit from AI revolutionMarket Growth Summary & High Accuracy Trade Signal Alerts - Newser
HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight - GlobeNewswire
How resilient is ALX Oncology Holdings Inc. stock in market downturnsMarket Trend Summary & Consistent Profit Trade Alerts - newser.com
Jefferies reiterates Buy rating on ALX Oncology stock, sees potential in cancer programs - Investing.com Canada
Can ALX Oncology Holdings Inc. hit a new high this month2025 Volatility Report & Daily Profit Maximizing Tips - newser.com
What analyst consensus says on ALX Oncology Holdings Inc. stockQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Will ALX Oncology Holdings Inc. stock outperform Dow Jones index2025 Fundamental Recap & Accurate Entry/Exit Alerts - newser.com
Is ALX Oncology Holdings Inc. stock attractive for long term wealth buildingVolume Spike & Expert Curated Trade Setups - newser.com
Is ALX Oncology Holdings Inc. stock attractive for hedge fundsEntry Point & Consistent Growth Equity Picks - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - Markets Financial Content
ALXO: Two high-value oncology programs advance toward key 2025 data with strong financial support - TradingView
Published on: 2025-11-19 06:30:37 - newser.com
Published on: 2025-11-19 06:25:55 - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Will ALX Oncology Holdings Inc. stock deliver long term returnsCEO Change & Entry Point Confirmation Signals - newser.com
Published on: 2025-11-18 23:37:11 - newser.com
Analyzing ALX Oncology Holdings Inc. with risk reward ratio charts2025 Trading Recap & Daily Growth Stock Tips - newser.com
Published on: 2025-11-18 12:31:34 - newser.com
ALX Oncology to Present at Upcoming Investor Conferences - The Manila Times
Published on: 2025-11-18 00:39:17 - newser.com
Statistical indicators supporting ALX Oncology Holdings Inc.’s strengthQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com
Will ALX Oncology Holdings Inc. outperform the marketJuly 2025 Catalysts & Community Verified Swing Trade Signals - newser.com
AIx 온콜로지 (ALXO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
AIx 온콜로지 주식 (ALXO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
0.56%
1.23%
자본화:
|
볼륨(24시간):